Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Feb 20, 2019 2:51pm
110 Views
Post# 29389655

RE:RE:RE:RE:RE:RE:CC

RE:RE:RE:RE:RE:RE:CCGenerally, I would agree with you.

However, Luc mentioned being the biggest pharma in Canada, over $1 Billion in sales and they mentioned at the AGM that they were looking for the next Billion for the market cap. 

It’s time for Luc to start delivering. Shareholders have been patient but we need some update on guidance. There are natural catalysts with Europe, NASH and F4 but we need execution. I’ve been consistent with that message since Trogarzo approval and execution has been lacking!

As for telling me to sell, you probably don’t want me to dump on the market as me and my colleagues would drop the stock right through the 52 week low.

bfw



jfm1330 wrote: This management has never been very promotional. It's not their style and it won't change. They believe achievments will make the price go up. If you want cheerleaders, it's not the company for you.

The SP last May distorted everything. It went too high too fast, and everybody are frustrated that it did not last, or frustrated that they did not sell to buy back a few months later at half the price. That being said, frustration won't change what happened and it's not management's fault. It is what it is.

Tanguay said Trogarzo should outperform Egrifta after one year. I think it shouldl be close to reality. Nobody was deeply misled by this statement. We will see tomorow what he has to say now. Again, whining over and over won't change anything. If you think Tanguay should leave, you should sell because he is not going anywhere.


Bullboard Posts